medigraphic.com

2015, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (3)

Quality of life in chronic obstructive lung disease. Experience in a hospital from western Mexico

Durán-Montes LA, Cisneros-Sandoval FJ, Gutiérrez-Román EA

Language: Spanish
References: 27
Page: 380-385
PDF size: 197.75 Kb.


ABSTRACT

Background: The chronic obstructive lung disease (COPD) is a common, expensive and preventable disease, and the evaluation of the quality of life in patients with the condition widens the scope of the results in their attention. The objective was to evaluate the health related quality of life (HRQL) according to the severity of the COPD.
Methods: Descriptive study. Patients with COPD diagnosis according with the severity and related with the HRQL measured using a specific questionnaire. Statistical analyses were made using χ2 or ANOVA in ranks according with the variables. A p value ≤ 0.05 was considered significant.
Results: 62 patients were included; 61% women. HRQL questionnaire showed the Activity dimension as the more negatively affected (65 ± 24 points, p ‹ 0.05). In the Impact dimension, severity groups III and IV were more affected compared with groups I and II (p ‹ 0.05). There was a directly correlation between a better FEV1 with better HRQL results (r2-0.544 p ‹ 0.0001).
Conclusions: HRQL is affected and clinically meaningful in patients with a major severity degree of the COPD condition. The parameters that better predicts a worst HRQL was % FEV1 and FVC.


REFERENCES

  1. Global Strategy for Diagnosis, Management and Prevention of COPD[Internet]., USA:Global Initiative for Chronic Obstructive Lung Disease (GOLD); [Uupdated 2013;citado 17 Feb 2014], Disponible en http:// www.goldcopd.org (Acceso 17 de Febrero de 2014).

  2. Murray CJL, López AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of dDisease Study. Lancet. 1997; 349(9064):1498-504.

  3. Menezes AM1, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV; PLATINO Team.Latinamerican Project for the Investigation of Obstructive Lung Disease. Chronic obstructive pulmonary disease in fi ve Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366(9500):1875-81.

  4. Reynales-Shigematsu LN, Rodríguez-Bolaños RA, Jiménez JA, Juárez-Márquez SA, Castro-Ríos A, Hernández-Ávila M. Costos de la atención médica atribuibles al consumo de tabaco en el Instituto Mexicano del Seguro Social. Salud Pública Mex. 2006; 48(Supl 1): S48-S64.

  5. Cazzola M, MacNee W, Martínez FJ, Rabe KF, Franciosi LE, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. ATS/ERS task force. 2008 Eur Respir Jour. 2008;31(2):416-4698.Texto libre en http://erj.ersjournals. com/content/31/2/416.long

  6. Güell, Rosa. Calidad de vida en la rehabilitación respiratoria. En: I Reunión española de calidad de vida relacionada con la salud. Noviembre 1999 Barcelona, España:17-20. Barcelona, España.

  7. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airfl ow limitation. The St George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327.

  8. Gill TM, Feinstein AR. A critical appraisal of the qualityof- life measurements. JAMA. 1994;272(8):619–626.

  9. Celli BR, MacNee W,; ATS/ERS Task Force.and committee members. Standards for the diagnosis and treatment of patients with COPD: Aa summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.Texto libre en http://erj.ersjournals. com/content/23/6/932.long

  10. Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R et al. Validity and reliability of the St George’s Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J. 1996;9(6):1160-66.Texto libre http://erj.ersjournals. com/content/9/6/1160.long

  11. Aguilar MG, Sotelo MC, Lara AG, García A, Sansores R, Ramírez A. Reproducibilidad del cuestionario respiratorio Saint George en la versión en español, en pacientes mexicanos con enfermedad pulmonar obstructiva crónica. Rev Inst Nal Enf Resp Mex. 2000;13(2):85-95.

  12. From the Global Strategy for Diagnosis, Management and Prevention of COPD[Internet]., USA:Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2007. Disponible en http://www.goldcopd.org

  13. Aguilar MG, García ML. Diferencias en calidad de vida en pacientes hospitalizados con epoc y asma.. Rev Inst Nal Enf Resp Mex. 2006;19(4):272-275.

  14. Miratvilles M, Ferrer M, Pont A, Zalacain R, Alvarez- Sala JL, Masa A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow-up study. Thorax. 2004.59(5):387-395. Texto libre en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC1746989/

  15. Anthonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, et al. Do GOLD stages of COPD severity really correspond to differences in health status? .2003. Eur Respir J. 2003; 22(3): 444-449. Texto libre en http://erj.ersjournals.com/content/ 22/3/444.long

  16. Jones PW , Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. y cols. Health-related quality of life in patients by COPD severity within primary care in Europe. 2011. Respiratory Medicine. 2011;.105(1): 57-66. Texto libre en http://www.resmedjournal.com/ article/S0954-6111(10)00390-2/fulltext

  17. Sin DD, Anthonisen NR, Soriano JB, Agustí AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006.28(6):1245-57. Texto libre en http://erj.ersjournals. com/content/28/6/1245.long

  18. Han MK, Curran-Everett D, Dransfi eld MT, Criner GJ, Zhang L, Murphy JR,et al. y cols. Racial differences in quality of life in patients with COPD. Chest. 2011;. 140(5):1169-1176.

  19. Berry CE, Drummond MB, Han MK, Li D, Fuller C, Limper AH, et al. y cols. Relationship between lung function impairment and healtrelated quality of life in COPD an interstitial lung disease. 2012. ChestHEST. 2012;.142(3):704-711.

  20. Sobradillo-Peña VS, Miravitlles M, Gabriel R, Jiménez- Ruiz CA, Villasante C, Masa JF.. Geographic variations in prevalence and underdiagnosis of COPD. results of the IBERPOC multicenter epidemiological study. Chest. 2000; 118(4):981-989.

  21. Soriano JB, Rodríguez-Roisin R. Chronic obstructive pulmonary disease overview. epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc. 2011;2011. (8):363-367.

  22. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez- Padilla R, Postma D, et al. y cols. An Offi cial American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010. (182)(5):693-718.

  23. Gross NJ. Chronic obstructive pulmonary disease outcome measurements : what’s important? What’s useful?. 2005. Proc Am Thorac Soc., 2005;. (2(4):267-271.

  24. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. y cols. Susceptibility to exacerbation in chronic obstructive pulmonary disease. 2010. N Engl J Med. 2010;363(12):1128-38.

  25. López-Vargas R, Domínguez ME, Sandoval RA, López-Muro M. Correlación entre la caminata shuttle y el cuestionario de Saint George’s en pacientes con enfermedad pulmonar crónica. Rev Inst Nal Enf Resp Mex. 2005;18(4):271-276.

  26. Lisboa B, Villafranca, Caiozzi G, Berrocal C, Leiva A, Pinochet R, et al. y cols. Calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica e impacto del entrenamiento físico. Rev Med Chile. 2001;129 (4) 359-366.

  27. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl.2003; 21: Suppl. 41:, 29s–35s.




2020     |     www.medigraphic.com